{"organizations": [], "uuid": "fb8dc4fd98b737cf64ef0ad32a4aba2dbb878cec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nabriva-announces-positive-results/brief-nabriva-announces-positive-results-for-pneumonia-treatment-idUSASC0A30J", "country": "US", "domain_rank": 408, "title": "BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.596, "site_type": "news", "published": "2018-05-21T20:08:00.000+03:00", "replies_count": 0, "uuid": "fb8dc4fd98b737cf64ef0ad32a4aba2dbb878cec"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nabriva-announces-positive-results/brief-nabriva-announces-positive-results-for-pneumonia-treatment-idUSASC0A30J", "ord_in_thread": 0, "title": "BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment", "locations": [], "entities": {"persons": [{"name": "lefamulin", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nabriva therapeutics plc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - Nabriva Therapeutics PLC:\n* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA\n* NABRIVA THERAPEUTICS PLC - COMPANY PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION\n* NABRIVA THERAPEUTICS PLC - LEFAMULIN MET ALL FDA AND EMA PRIMARY ENDPOINTS AND WAS SHOWN TO BE GENERALLY WELL TOLERATED\n* NABRIVA THERAPEUTICS PLC - PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T20:08:00.000+03:00", "crawled": "2018-05-22T19:28:36.005+03:00", "highlightTitle": ""}